Updates on the Management of Ocular Vasculopathies with VEGF Inhibitor Conbercept

ABSTRACT

Purpose: To provide a detailed review on the therapeutic efficacy of conbercept for the management of ocular vasculopathies.

Methods: A comprehensive literature search of various electronic databases was performed.

Results: Ocular vasculopathy is one of the major causes of visual impairment and blindness which includes a range of disorders. Vascular endothelial growth factor (VEGF) regulates angiogenesis, enhances vascular permeability, and drives the formation of neovascularization. Anti-VEGF therapy has been shown to prevent vision loss or potentially improve vision in patients with exudative or neovascular retinal disease. The most recent anti-VEGF drug in China is conbercept. In the USA and Europe, bevacizumab is the most recently approved anti-VEGF agent.

Conclusions: Conbercept serves as another anti-VEGF option for patients with neovascular AMD and other retinal vascular disorders. There have not been many clinical trials that study conbercept as compared with other currently available anti-VEGF drugs. There is a need for large-scale, well-designed, randomized clinical trials to ensure its long-term safety and efficacy and to determine if it has any advantages over other anti-VEGF agents.

KEYWORDS:

• Age-related macular degeneration
• branch retinal vein occlusion
• conbercept
• corneal neovascularization
• diabetic retinopathy
• myopic choroidal neovascularization
• neovascular glaucoma
• polypoidal choroidal vasculopathy
• vascular endothelial growth factor

Declaration of conflicting interests

The authors report no conflicts of interest.

Additional information

Funding

Supported by Hebei Provincial Department of Science and Technology, Shijiazhuang, Hebei, China [grant No. 182777112D].